rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Daxor Corporation - Closed End Fund

DXR · Nasdaq

Health CareMedical DevicesNot moving yet

DXR stood above a rising 150-day average in 17 of the last 52 weekly readings, and has been out of that trend for the last 35 weeks. It is 3.3% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 35
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$38K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
13 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 17 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$33KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months6
Sale orders, 12 months0
Buyers · sellers4 · 0
WhoDidSharesTraded
Michael Richard FeldschuhChief Executive Officerbought1,000at $9.078 Apr 2026filed 10 Apr 2026
Robert J. MichelChief Financial Officerbought1,000at $9.9031 Mar 2026filed 31 Mar 2026
John JefferiesChief Medical Officerbought3,656at $0.0020 Mar 2026filed 24 Mar 2026
John JefferiesChief Medical Officerbought2,285at $0.0020 Mar 2026filed 24 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders13+1 on the quarter
New · exited2 · 1
Reported value$1.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 202648,831$496K+551+1.1%
Aristides Capital LLCreduced · filed 13 Aug 202641,689$429K-30.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 202629,421$303K+1,410+5.0%
SUSQUEHANNA INTERNATIONAL GROUP, LLPadded · filed 14 Aug 202627,131$275K+13,411+97.7%
NANO CAP NEW MILLENNIUM GROWTH FUND L Punchanged · filed 14 Aug 202612,500$129K00.0%
Crescent Grove Advisors, LLCadded · filed 10 Aug 202612,423$128K+1,700+15.9%
SBI Securities Co., Ltd.added · filed 23 Jul 20263,131$32K+3+0.1%
MORGAN STANLEYunchanged · filed 13 Aug 20263,087$32K00.0%
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 20261,037$11K00.0%
OSAIC HOLDINGS, INC.unchanged · filed 14 Aug 2026500$5,14500.0%
31 Mar 2023 – 30 Jun 2026
2813Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

John Jefferies Company insiderChief Medical Officer · last 28 Aug 20262 · 0
Caleb DesRosiers Company insiderDirector · last 23 Jun 20261 · 0
Edward Feuer Company insiderDirector · last 23 Jun 20262 · 0
Henry D. Cremisi Company insiderDirector · last 23 Jun 20260 · 0
Jonathan Adam Feldschuh Company insiderChief Scientific Officer · last 23 Jun 20262 · 1
Joy S. Goudie Company insiderDirector · last 23 Jun 20261 · 0
Michael Richard Feldschuh Company insiderChief Executive Officer · last 23 Jun 202638 · 1
Robert J. Michel Company insiderChief Financial Officer · last 23 Jun 202613 · 0
Estate Of Joseph Feldschuh Company insider10% owner · last 18 Sep 20230 · 0
James A. Lombard Company insiderDirector · last 11 Jul 20230 · 0
Bernhard Saxe Company insiderDirector · last 25 Jun 20201 · 0
Martin S. Wolpoff Company insiderDirector · last 25 Jun 20208 · 2

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%
PLSE Pulse BiosciencesLeading+33%
INFU InfuSystems HoldingsLeading+27%
SMTI Sanara MedTechLeading+26%
ITGR Integer HoldingsLeading+23%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2011 · to 31 Dec 201154.9%
Operating profit marginFY 2011 · to 31 Dec 2011-400%
Free cash flow marginFY 2011 · to 31 Dec 2011-459%
Return on capital employedFY 2011 · to 31 Dec 2011-15.9%
Research spendFY 2011 · to 31 Dec 2011187%
Share count trendFY 2011 · to 22 Mar 2012-0.1%
Cash and equivalentsFY 2011 · to 31 Dec 2011$60K
Free cash flowFY 2011 · to 31 Dec 2011−$6.6M

Analyst forecasts

No analyst forecasts yet.